141 related articles for article (PubMed ID: 34250408)
1. Exceptional Response to Trastuzumab in a Heavily Pretreated Patient With ERBB3-Mutated Metastatic Breast Cancer.
Parmar S; Keck JM; Kong B; Look R; Johnson B; Patterson J; Labrie M; Guimaraes AR; Corless CL; Beadling C; Kolodzie A; Bergan R; Gray JW; Mills GB; Mitri ZI
JCO Precis Oncol; 2021; 5():. PubMed ID: 34250408
[No Abstract] [Full Text] [Related]
2. Exceptional Response to Pembrolizumab and Trastuzumab in a Heavily Pretreated Patient With HER2-Positive TMB-H and MSI-H Metastatic Breast Cancer.
Li A; Goodyear S; Fuss C; Mitri Z
JCO Precis Oncol; 2021 Nov; 5():904-909. PubMed ID: 34994619
[No Abstract] [Full Text] [Related]
3. Trastuzumab emtansine in HER2-positive metastatic breast cancer: what is the best sequence?
Ricci F; Le Tourneau C
Chin Clin Oncol; 2018 Feb; 7(1):3. PubMed ID: 29156892
[No Abstract] [Full Text] [Related]
4. Evaluation of the prognostic value of all four HER family receptors in patients with metastatic breast cancer treated with trastuzumab: A Hellenic Cooperative Oncology Group (HeCOG) study.
Koutras A; Lazaridis G; Koliou GA; Kouvatseas G; Christodoulou C; Pectasides D; Kotoula V; Batistatou A; Bobos M; Tsolaki E; Papadopoulou K; Pentheroudakis G; Papakostas P; Pervana S; Petraki K; Chrisafi S; Razis E; Psyrri A; Bafaloukos D; Kalogeras KT; Kalofonos HP; Fountzilas G
PLoS One; 2018; 13(12):e0207707. PubMed ID: 30521571
[TBL] [Abstract][Full Text] [Related]
5. Relapsed and De Novo Metastatic HER2-positive Breast Cancer Treated With Trastuzumab: Tumor Genotypes and Clinical Measures Associated With Patient Outcome.
Kotoula V; Tsakiri K; Koliou GA; Lazaridis G; Papadopoulou K; Giannoulatou E; Tikas I; Christodoulou C; Chatzopoulos K; Bobos M; Pentheroudakis G; Tsolaki E; Batistatou A; Kotsakis A; Koutras A; Linardou H; Razis E; Res E; Pectasides D; Fountzilas G
Clin Breast Cancer; 2019 Apr; 19(2):113-125.e4. PubMed ID: 30545790
[TBL] [Abstract][Full Text] [Related]
6. Relationship between tumor biomarkers and efficacy in MARIANNE, a phase III study of trastuzumab emtansine ± pertuzumab versus trastuzumab plus taxane in HER2-positive advanced breast cancer.
Perez EA; de Haas SL; Eiermann W; Barrios CH; Toi M; Im YH; Conte PF; Martin M; Pienkowski T; Pivot XB; Burris HA; Stanzel S; Patre M; Ellis PA
BMC Cancer; 2019 May; 19(1):517. PubMed ID: 31146717
[TBL] [Abstract][Full Text] [Related]
7. Duration of trastuzumab maintenance in HER2-positive metastatic breast cancer patients with radiological complete remission: Robust predictive markers are needed!
Altundag K
J BUON; 2020; 25(2):1269. PubMed ID: 32521942
[No Abstract] [Full Text] [Related]
8. Intrathecal Trastuzumab Treatment in Patients with Breast Cancer and Leptomeningeal Carcinomatosis.
Park WY; Kim HJ; Kim K; Bae SB; Lee N; Lee KT; Won JH; Park HS; Lee SC
Cancer Res Treat; 2016 Apr; 48(2):843-7. PubMed ID: 25761487
[TBL] [Abstract][Full Text] [Related]
9. Trastuzumab-emtansine might affect the survival outcome by reversing increased platelet-to-lymphocyte ratio in HER2-positive metastatic breast cancer patients.
Altundag K
J BUON; 2019; 24(1):407. PubMed ID: 30942001
[No Abstract] [Full Text] [Related]
10. MicroRNA-21 as a predictor and prognostic factor for trastuzumab therapy in human epidermal growth factor receptor 2-positive metastatic breast cancer.
Badr M; Said H; Louka ML; Elghazaly HA; Gaballah A; Atef Abd El Mageed M
J Cell Biochem; 2019 Mar; 120(3):3459-3466. PubMed ID: 30246355
[TBL] [Abstract][Full Text] [Related]
11. High p95HER2/HER2 Ratio Associated With Poor Outcome in Trastuzumab-Treated HER2-Positive Metastatic Breast Cancer NCCTG N0337 and NCCTG 98-32-52 (Alliance).
Chumsri S; Sperinde J; Liu H; Gligorov J; Spano JP; Antoine M; Moreno Aspitia A; Tan W; Winslow J; Petropoulos CJ; Chenna A; Bates M; Weidler JM; Huang W; Dueck A; Perez EA
Clin Cancer Res; 2018 Jul; 24(13):3053-3058. PubMed ID: 29530935
[No Abstract] [Full Text] [Related]
12. Germline single nucleotide polymorphisms in ERBB3 and BARD1 genes result in a worse relapse free survival response for HER2-positive breast cancer patients treated with adjuvant based docetaxel, carboplatin and trastuzumab (TCH).
Coté D; Eustace A; Toomey S; Cremona M; Milewska M; Furney S; Carr A; Fay J; Kay E; Kennedy S; Crown J; Hennessy B; Madden S
PLoS One; 2018; 13(8):e0200996. PubMed ID: 30071039
[TBL] [Abstract][Full Text] [Related]
13. [New approval: Trastuzumab-deruxtecan for metastatic breast cancer HER2].
Minot-This MS; Bellesoeur A
Bull Cancer; 2021 Sep; 108(9):783-784. PubMed ID: 34144792
[No Abstract] [Full Text] [Related]
14. Evaluating Trastuzumab in the treatment of HER2 positive breast cancer.
Jaques R; Xu S; Matsakas A
Histol Histopathol; 2020 Oct; 35(10):1059-1075. PubMed ID: 32323293
[TBL] [Abstract][Full Text] [Related]
15. Trastuzumab emtansine for HER2-positive breast cancer.
Venkatesan P
Lancet Oncol; 2016 Dec; 17(12):e528. PubMed ID: 27866859
[No Abstract] [Full Text] [Related]
16. Prolonged Responses With Trastuzumab Emtasine Treatment of Human Epidermal Growth Factor Receptor 2-positive Metastatic Breast Cancer Refractory to Trastuzumab and Pertuzumab: Systematic Review of Evidence.
Martin Huertas R; Fernández Abad M; Corral de la Fuente E; Serrano Domingo JJ; Martínez Jáñez N
Clin Breast Cancer; 2021 Oct; 21(5):391-398. PubMed ID: 33549470
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of the Role of p95 HER2 Isoform in Trastuzumab Efficacy in Metastatic Breast Cancer.
Rigakos G; Razis E; Koliou GA; Oikonomopoulos G; Tsolaki E; Sperinde J; Chrisafi S; Zarkavelis G; Pazarli E; Batistatou A; Kourea HP; Papakostas P; Bafaloukos D; Asimakopoulou NI; Res E; Kotsakis A; Pectasides D; Koutras A; Christodoulou C; Fountzilas G
Anticancer Res; 2021 Apr; 41(4):1793-1802. PubMed ID: 33813384
[TBL] [Abstract][Full Text] [Related]
18. Ado-trastuzumab emtansine (T-DM1) in HER2+ advanced breast cancer patients: does pretreatment with pertuzumab matter?
Fabi A; Giannarelli D; Moscetti L; Santini D; Zambelli A; Laurentiis M; Caruso M; Generali D; Valle E; Leonardi V; Cannita K; Arpino G; Filippelli G; Ferretti G; Giampaglia M; Montemurro F; Nisticò C; Gasparro S; Cognetti F
Future Oncol; 2017 Dec; 13(30):2791-2797. PubMed ID: 29182361
[TBL] [Abstract][Full Text] [Related]
19. ABP 980: A Trastuzumab Biosimilar.
Dhillon S
BioDrugs; 2018 Oct; 32(5):511-514. PubMed ID: 30264234
[TBL] [Abstract][Full Text] [Related]
20. The impact of human epidermal growth factor receptor 2 neoadjuvant monoclonal antibody (trastuzumab) therapy in ductal carcinoma in situ of the breast.
Parham DM; Pinder SE
Histopathology; 2017 May; 70(6):1009-1011. PubMed ID: 27943389
[No Abstract] [Full Text] [Related]
[Next] [New Search]
